Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks mad - never doubted you for a second - not for one second.....
Instead of listing the 170 reasons, he sold out his entire position at the opening - 14,681 shares - less than $35 - made a buck or two there... apparently may get back in if it drops below .0020 to get ready for the next run-up. :)
Hey Steve - I'm getting blanks for the one poster I have on ignore - beautiful system, but also an unusual string of deletes unrelated to me as I did not post. Is it my system, or was there a battle going on which the mods appropriately deemed to be off-topic or of no interest?
Thanks
Perfect fuente - because those in the industry well know that if a Big Pharma firm infringes, that is a wide-open door for another big player to go to BIEL and say, "let's make a deal, your going to be drained and obliterated by patent infringement you cannot defend, but if we are partners, we will bankroll your litigation."
Patent infringement is a profit center in many pharma companies, they know the game and are the best at it. Big Pharma does not take the clear risk of knowingly infringing, knowing they can be completely shut down later with a huge judgment.
From experience, you're right 3pointer - there are numerous IP and patent infringement firms here in America, I know of 2 in the UK - all do contingency work based on success.
On the other hand, if this GSK stuff is at all true, then all the Big Pharma boys will never, ever allow GSK to jump ahead - their pipelines are essentially empty, with new combination drugs waning somewhat.........PEMF is virgin territory for the Big Boys and remember Alex Gorsky, the relatively new CEO at J&J, was Director of the J&J Devices Division before he got the nod for the top job there. Can anyone believe they are not watching each other every minute of every day like vultures?
Buy em now boys, this is the .0015 of approx 6 weeks ago, with the FDA meeting scheduled in 42 days
Brilliant id - thanks very much for the initiative and for informing us.
Thanks to you and Dubb on the notice fuj.
I was amazed at a latter part of it though....
"The meeting was announced in the Federal Register of November 29, 2012 (77 FR 71195). The meeting is postponed because key participants were unavailable due to unforeseen scheduling conflicts. In the meantime, FDA analysis of industry-submitted documents is ongoing."
Does "is ongoing" simply mean they weren't ready for April 5th? Who knows!
But, if that announcement is true and accurate, then, as has become my current mantra, - we ain't dead yet! Yes, I am a shareholder, but I am also a completely amazed and satisfied ActiPatch user and that the FDA continues to work on the issues is good news to me. Go FDA!
Hey edbi
Using your formula in 29491 and tjshooker's number in 29494 the shake-out is -
YOURS
BIEL pps ~.35 (1% of 10 billion dollar market)
The worldwide market for THERAPEUTIC AGENTS IS $$$
$10,000,000,000 (10 BIL), (1% OF 10BIL=100MIL REV. @ 60% MARGIN (MARGINS FOR BIEL HAVE BEEN OVER 60%) = $60 MIL PROFIT DIVIDED BY ~2.7 BIL SHARES OS = $.022/SHARE @ PE AVG OF 16 = $.35 PPS,,,,,and that's not hyping to much.....BIEL will prevail !!!!!!!!!!!!!!!
REVISED
BIEL pps ~ $1.244 (1% of 35 billion dollar market in 2015)
The 2015 worldwide market for THERAPEUTIC AGENTS IS $$$
$35,000,000,000 (35 BIL), (1% OF 35BIL=350MIL REV. @ 60% MARGIN (MARGINS FOR BIEL HAVE BEEN OVER 60%) = $210 MIL PROFIT DIVIDED BY ~2.7 BIL SHARES OS = $.0778SHARE @ PE AVG OF 16 = $1.24 PPS,,,,,and that's not hyping to much.....BIEL will prevail !!!!!!!!!!!!!!!
END
Let's say this is off by 75% - I'm a cautious fellow - is 31 cents so bad? Off by 90% = 12.4 cents? Pick a number.
Re - That approach should help us kid.......thanks. Do you think the you - know - what just flew the coop?
The reality is that the information, if it exists, will not change a thing. The BIEL products have merit and the shares should be trading at a much higher price, IMO. However, I would like to know what mad's birdie knows, wouldn't you?
That should help us kid.......thanks.
I'm just getting into my car and will be driving for a few hours diarch - suggest you please find a mad post, clik on his name and quickly review his recent posts.
If you're correct, it may only have been a moment of pique, most here are very frustrated, but it's not the product, as you probably know. Cheers
Sort of have to agree with steelyeye madp.
I have always felt comfortable and accepted that you had confidence in what the birdie was advising you. I also think you would agree that your info put you in a very unique position, as compared to the rest of us. I thank you for sharing what you have so far, but the price swings of recent days, plus the amount of information circulating, lead me to ask if you can shed any further thoughts with us, please?
Even if you have to massage the information in such a way that you protect your source, that would be OK with me. What do you think?
No firedancer.....I will decide when enough of the birdie is enough for me.
And the only one thing, of three, that I know that is 100% accurate is that I don't know. Another is that the birdie has been right so far. The third thing on the bottom line is that you and I don't know what mad knows.
did your faithful little birdie help you determine that it was the bottom?
I thought he looked pretty good, for a guy who just sat beside the FDA Director of Compliance at the Johns Hopkins gala dinner....just kidding
steve - may I please share your new heart machine - someone says this is the bottom
dit le petite oiseau?
I inferred that you were.....I guess the FDA doesn't realize ASA produces heat by the release of its electrons? Should be banned, or at the very least be changed in its classification to Rx under a physician's supervision. What a laugh that would be for the makers of Aspirin. Produces heat? Nope. Banned!
I also guess that MRI's should immediately be banned as they release tremendous heat - amazing. This stuff is early college sciences, how come the lag at the FDA? I really wonder if 200 more people would've changed the culture - overkill comes to mind, but that would be too ironic!
Then, fuente, can it not be presented, as you have described, that BIEL technology is in both camps, depending on the medium?
That BIEL's electro-magnetic current is initially a PEMF, non-thermal entity, as it penetrates through the epidermis, which is the nonvascular and nonsensitive protective layer of the inner skin, or corium, which, because of its lower sensitivity does not react in a heat-producing manner, whereupon entering the corium, or subcutaneous tissue, below the epidermis, that same entity, the same PEMF does cause the more sensitive corium to react initiating a therapeutic, minute, increase in temperature which both aids the bodies naturally produced endorphins in reducing sensitivity to pain, while simultaneously stimulating increased circulation at the molecular level.
The epidermis and the corium are as different to the PEMF as night and day; they react to it differently in every way. Another way of illustrating the different responses of the epidermis and the corium to the same PEMF is by comparing a hand immersed in tepid water, on which there is a large burn blister. Puncture that blister and hold the same hand with the exposed inner tissue in the same water and feel the greater pain sensation.
I fail to see why the FDA cannot recognize that each skin component behaves differently without harm to the body, with a minute increase in temperature. It is well accepted in science and medicine and even by the FDA that the body will react violently to a change of circumstance measuring few parts per million.
Thanks to you and tjs, kid, and especially fuente for making the current status so clear.
Lemme ask this. Notwithstanding that CEO Whelan was scheduled to speak on behalf of BIEL at the FDA called public meeting April 5, is it also true that the work of the committee he was to speak to has virtually nothing to do with the classification, or re-classification of BIEL's products and whether they will be approved for OTC, because BIEL's application is actually under appeal before a different body, the integrity executives of the FDA?
And, may one presume that BIEL lies in limbo land between a potentially very expensive approval process and a simple re-classification by the FDA here, I simply want to get it clear in my mind.
Because to me this is getting more and more simple. If BIEL in spite of earlier ineptitude in the process, granted, has not been assessed fairly, or scientifically appropriately, then of course they stand a good chance at appeal. And, if they then fall under another regulatory process that is assessing if there should be a new category for PEMF and that it is safe and efficacious for OOTC sales, then who cares? Is the bottom line not that the technology works amazingly well and there has never been a negative side-effect? Thanks.
Thanks walker - I went thru the same motions as yesterday, the info popped up, thereby assuring me that it is so recent that USPTO had simply not posted the data to the public yet.
The company is obviously enhancing its IP protection, which is very costly. Other than parts of Asia, I love patent protection.
my earlier slightly altered
stock, you're a smart guy and I've said so before. Although the lack of BIEL traction is upsetting, the reality is BIEL is operating as a start-up looking for regulatory approval, that is being delayed incredibly by the FDA and probably its own ineptitudes in the application process learning curve and operating on shoe strings. As a result, BIEL is still in business and operating at a burn rate of between $85K and $100K a month if one considers SP in the $ .0015 range, less commissions and fee grabbers.
My initial take is that is not out of this world crazy, considering the potentials and shareholder upside. The higher the price the less the need to dilute shares. If I were CEO, I would look to the folks managing the dilution / selling of those shares to see if the price could be permitted to float higher, especially given the increased demand for stock, thereby giving the company more survival financing and less dilution.
How about show the document - all grudge issues and nonsense
ok - no problem, thanks - I referred to you as a smart guy, as I've said before....and then wondered if I might be impolite to refer to you as a guy, if you are actually a lady, so I said - until gender confirmed so as to avoid insulting you - no one on earth could have been more polite and respectful. Someone may have misinterpreted my good intentions or it may be automatic if the word 'gender' pops up, not to worry.
3 - 4 balais apparemment
toujours suivant M. mad
issues.....ignore
You crack me up Steve. I understand your frustration, but I can't stand the thought of you smashing heart machine after heart machine. I am also am very frustrated and know the management and sales traction, drug store chain issues, but I also feel confident that there are other aspects to this we don't know, so I try to remain patient that we will win in spite of the corporate issues. Meantime, thank you for your angry humor.
I don't think you did either Casper, but others did so.
Correct diarch - sumpin's up - wish I knew what.
Consider that we now have madp's birdie and your dogs out scouting in the bushes - find out who knows because someone does.
There is just too much data and shares traded.
Casper - you and steeleye have no 'n idea how much I would like to sit down for a coffee and trade intel - I e-mailed steeleye at his/her e-mail address and have rec'd no reply as yet - there is something going on in BIELville, based on the intel, I can smell it.
Hey Steve - went to USPTO site and searched for 8,412,328 - it's not up on the PTO system as yet and I was advised that the data is current to March 26. Would you, or another poster mind confirming my effort please? And, if confirmed, can we rely on assuming that BIEL may have received notice of the issuance of the patent post March 26? I am also wondering if the issuance news in the PR is a supplemental to the main BIEL patent? Seems to me it's good news, if true, because patent lawyers cost a lot of money, over a long period of time - this would not have come cheaply, if true.
Hey Steve - I don't buy the "scheduling conflicts" of key participants at all. The April 5th meeting involving numerous applicant firms and the BIEL technology was scheduled in November (?), 5 months ago, when all key participants would obviously confirm to the staff member they could attend April 5th. Then, March 8, or so, one or more of those key participants popped up and said, "opps, sorry, busy that day"? Nope, don't buy it. I can't see anyone at FDA risking their credibility by hanging applicant firms out to dry, as well as their colleagues inside who now have that space open.
So, we need to know what is really going on. As I said last week, if the news was to be negative in terms of OTC approval for BIEL and other applicant firms, the FDA would make that determination without the public meeting? A total reversal to be advised later? Nope.
Is is related to a more definitive undrstanding by the FDA of the need or viability of a new device category, which heretofore they did not have a handle on because of a lack of staff qualified to assess PEMF?
Has someone in DC asked what is going on and why all the delays and undercurrents about new categories? I hope so, about time. Is it about face-saving?
The few things we know are BIEL products work, there has been zero information about negative side-effects, the company announces today about new IP patent protection at USPTO (thanks wyatt) and approved for OTC sales in Canada, the UK and elsewhere.
There is someone somewhere who can confirm the reason for the 5 week delay in the public meeting the FDA called by them for April 5th to May 10, if the PEMF matter has actually been added to the May 10th meeting agenda. Someone knows.
There ya go - sanity prevails as it should.
The only possible subterfuge now is if the 'key participants' referred to, presumably on the FDA side of things have positions that need more refinement. Otherwise April just became May - terrific - we ain't dead yet. Things are exactly as they were a week ago, except there a few weeks have been tacked on for potential investors to learn of the BIEL and the issues.
yes - thanks speakhim and yankee - Wow - as I was going thru posts, I was thinking, someone knows exactly what's going on - I wonder if anyone knows AW and can enquire of him? Perhaps that can still happen to confirm Paul? It's all about information and someone has it.
Thanks guys - as I said I'm jammed for time - sorry - read the PR and my nose says that IF the FDA wanted to get rid of the applicant firms on these issues, they would have gone through with the public meeting long-scheduled (3 months or more?) for April 5th and published its (pre-determined) findings and decision accordingly - BUT that is not what just happened. IMO that is hugely positive for the applicant firms.
For balance, the other side of the coin may be that if there is new information of a negative flavor supporting a 'No' from the FDA after the April 5th meeting in its findings and decision, then the April 5th meeting would happen.
Can one assume that either the FDA is saying internally "we must get this right" and is postponing the meeting, not cancelling it? So, my take is it's caution, new info, or intervention from above, either state or DC. Otherwise, why postpone?
zemun - sorry, I'm jammed for time today. Would you please advise the exact timing of your information and from whom you received it and/or the source?
This may just be a classic case of BIEL (and the other applicant firms) just avoided getting a no. Which is to say, "we ain't dead yet"
Of course, the reason is the key element. Was it because someone in the administration at the USFDA finally recognized that they are so far off base, according to BIEL and many scientifically knowledgeble experts in the field, that they need to develop the appropriate next steps or actions, rather than more simple obfuscation?
Or, at another more appropriate level, did someone in Maryland hit the alarm button about Maryland granting financial funds to BIEL to expand its' business, while they are stagnating in the regulatory application process at the FDA?
Or, did the good Lady Senator from Maryland, or someone else at the top of the food chain in DC finally "get it" and stop the train for quick re-assessment? Whatever, it ain't a no, maybe it's finally face-saving time.
did u check to see if you have mail?
Thanks very much diarch - stupid of me
My notes show 12.99 pounds Sterling = $20.04 Canadian = $19.71 USD
Must've grabbed the wrong number - sorry to all for the inconvenience - apparently it's only steve who can't spell worth a chit, the rest of us are just dummies and foolish pumpers. :)
Thanks again
Just went on healfasttherapy.com - they are charging $19.95 for what looks like an ActiPatch, roughly the same pricing strategy as in Canada and the UK.
Does BIEL not understand that people will pay a lot more for food products, therapies and solutions for their pets than they will for themselves or their children? Lower the human prices and 'buy' customer acceptance until the drug product buying habits are changed, or continue to languish with zero sales globally. Now I 'get' steve's long-standing frustrations.
OMG steve. I saw your post that my asking "Is it price?" seemed to you to be a good question. I dug a little and see that Amazon UK pricing of 12.99 pounds Sterling is equal to $20.04 Canadian dollars, yet, the ActiPatch.ca website prices them at $29.95 (or $19.71 USD)
I am certainly not a BIEL expert, but I'm not a fool either, why would Canadians pay almost 50% more? WHat is the true cost to manufacture BIEL's products? My gut tells me that BIEL's pricing strategies are based on the assumption that it is already successful in the retail marketplace!
News flash! BIEL, your products are not selling anywhere on earth, in any significant numbers. Therefor price your goods on an intrductory basis, why not?. If you do not, the customers will continue to walk by your goods and buy Tylenol! Your retailers will continue to sell no product and make no money. Your global distributors, every last one of them, will continue to make no money, on zero sales, zero inventory replenishment and you will continue to bumble along reporting no sales. Steve is right, you are not, you're pricing yourself out of sales, not breaking customer's habits! Currently, you are number 11 on the block behingd the top 10 sellers of drug pain killers, therefor you have to break the ice.
As a user of ActiPatch, and I'm looking at one right now, product and packaging, and a little mark-up, all in, I estimate to cost $3 bucks, tops. I kick myself at not noticing this before and there is not a damn thing I can do about it, as a shareholder. You people have priced your goods as if you are already and accepted, product of choice for millions, world beater. have priced yourself out of being able to say to the customer, "we are a safe, drug-free, no side-effect alternative to pain management and promotion of healing, something Tylenol and its' peers can never do. Try me! No drugs and no side-effects!"
Wade in here good guys, am I crazy?